Clinical Trial Update: Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on peptide receptor radionuclide therapy with yttrium-90 DOTATOC in relapsed/refractory diffuse large B-cell lymphoma and mantle c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• 90Y-DOTATOC (DOTATOC)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: DLBCL, MCL | Phase 2 | Status: TERMINATED